Optimization of scAAVIL-1ra In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis.
about
The Challenge and the Promise of Bone Marrow Cells for Human Cartilage RepairInflammation in joint injury and post-traumatic osteoarthritisRNA Interference Mediated Interleukin-1β Silencing in Inflamed Chondrocytes Decreases Target and Downstream Catabolic Responses.Adeno-associated viral vectors show serotype specific transduction of equine joint tissue explants and cultured monolayersMechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors.Advances and challenges in gene-based approaches for osteoarthritis.Use of tissue engineering strategies to repair joint tissues in osteoarthritis: viral gene transfer approaches.Tissue-engineering strategies to repair joint tissue in osteoarthritis: nonviral gene-transfer approaches.Cartilage tissue engineering: recent advances and perspectives from gene regulation/therapy.Advances in treatment of achondroplasia and osteoarthritis.Gene therapy for human osteoarthritis: principles and clinical translation.Recent tissue engineering-based advances for effective rAAV-mediated gene transfer in the musculoskeletal system.New cell engineering approaches for cartilage regenerative medicine.Tissue-engineered cartilage with inducible and tunable immunomodulatory properties.scAAVIL-1ra dosing trial in a large animal model and validation of long-term expression with repeat administration for osteoarthritis therapy.Inflammation-induced transgene expression in genetically engineered equine mesenchymal stem cells.Cytokine-induced interleukin-1 receptor antagonist protein expression in genetically engineered equine mesenchymal stem cells for osteoarthritis treatment.
P2860
Q35783686-B6CDC69A-DB78-4955-9C02-F54C42B99B5DQ36242292-54B777F2-5C25-4C31-8578-2A7E6177AA34Q36747491-78D8CC8E-99DE-47D7-B464-EE9B0B63D93BQ36972596-6A998001-9EF6-47AE-8609-22EEC3C7ABD5Q37336413-550AD835-4B6D-4B52-92C8-B962ACBA231AQ38134331-690C5D17-8A60-45C0-B510-F863B7FED120Q38245620-CB70BDBB-0279-4DE8-B1DB-C05664C17712Q38245621-66A73CA6-6593-4B40-A31C-8462010DCEE8Q38345989-C268D707-7F9A-4CC5-AF54-C6B6E740A322Q38601075-7FA7A722-4F1C-4239-8B52-EF0ADF3EE9B3Q38642703-AAB8EFEF-84F4-427E-951B-56CD264E3450Q38843434-955A367C-EC11-463C-B900-5398B1434893Q39217099-2AD6FBE8-6D51-4BCE-9AF9-4675F24CD3B4Q40380301-AB6F45BE-9336-4ABC-86FB-F7C39AF65AAFQ41493963-EA09436B-9DD3-4C70-9128-E811BEE13222Q45854928-71CF6436-3704-4223-8258-39B342BF8403Q52613681-BFEA7744-45B6-44FF-837A-CD05C10BD498
P2860
Optimization of scAAVIL-1ra In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Optimization of scAAVIL-1ra In ...... r Treatment of Osteoarthritis.
@ast
Optimization of scAAVIL-1ra In ...... r Treatment of Osteoarthritis.
@en
type
label
Optimization of scAAVIL-1ra In ...... r Treatment of Osteoarthritis.
@ast
Optimization of scAAVIL-1ra In ...... r Treatment of Osteoarthritis.
@en
prefLabel
Optimization of scAAVIL-1ra In ...... r Treatment of Osteoarthritis.
@ast
Optimization of scAAVIL-1ra In ...... r Treatment of Osteoarthritis.
@en
P2093
P2860
P356
P1476
Optimization of scAAVIL-1ra In ...... r Treatment of Osteoarthritis.
@en
P2093
C Wayne McIlwraith
Jennifer N Phillips
Joshua C Grieger
Laurie R Goodrich
R Jude Samulski
Stacey B Foti
Steven J Gray
P2860
P356
10.1038/MTNA.2012.61
P577
2013-02-05T00:00:00Z